Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Trial Testing the Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Summary

The purpose of this phase 2 trial is to evaluate the safety and efficacy of CDX-1140 alone or in combination with CDX-301 followed by surgery in patients with pancreatic ductal adenocarcinoma.

General Information

NCT#: NCT04536077
Study ID: 202011125
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI), Celldex Therapeutics, Washington University School of Medicine, The Foundation for Barnes-Jewish Hospital
Therapies Used in This Trial: CDX-1140, CDX-301

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search